From Medical News today:
"Chronic lymphocytic leukemia (CLL) patients who stopped taking the kinase inhibitors (KIs), ibrutinib or idelalisib, had mostly favorable outcomes when they switched to the alternate therapy, according to a large multi-center study, conducted in part at the Perelman School of Medicine at the University of Pennsylvania.
:
:
Patients who discontinued ibrutinib or idelalisib and went on to be treated with the other kinase inhibitor had durable responses, the researchers report. The objective response rate was 50 percent and median progression free survival was 11.9 months. Responses were most durable for patients who discontinued ibrutinib or idelalisib because they experienced side effects that made it difficult for them to continue taking the drug." (My emphasis)
medicalnewstoday.com/releas...
Neil
Photo: Bee approaching a naked lady/Easter lily bloom.